Healio

C5a agonist therapy may be a 'game changer' in ANCA vasculitis

Please provide your email address to receive an email when new articles are posted on . Targeting the complement pathway using a C5a agonist may be a “game changer” in anti-neutrophil cytoplasmic ...
Seeking Alpha

InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients

Vilobelimab is the first authorized drug to control complement factor C5a, a protein that plays an important and often harmful role in the body's immune response FDA granted EUA based on Phase III ...
News Medical

Multiomic comparison shows a reduction in circulating monocytes correlated with persistent post-COVID-19 pulmonary fibrosis

In a recent study posted to the medRxiv* server, researchers identified distinguishing immune features of coronavirus disease 2019 (COVID-19) in patients with late-resolving pulmonary fibrosis (LR ...
News Medical

Phenotypic changes in monocytes from COVID-19 patients

The coronavirus disease 2019 (COVID-19) can significantly alter host immune and inflammation function. In fact, many researchers have suggested that some of the symptoms observed in ‘long COVID could ...
Nasdaq

InflaRx Announces Presentation of New C5a and Vilobelimab (IFX-1) Data from Phase IIB SHINE Study at the 2021 Virtual European Hidradenitis Suppurativa Foundation Conference

Significantly elevated baseline C5a levels occur in hidradenitis suppurativa (HS) patients Vilobelimab dose-dependently suppresses C5a levels over time accompanied by the previously reported reduction ...